Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1;43(8):892-900.
doi: 10.1097/MNM.0000000000001592. Epub 2022 Jun 10.

Differences in tumor-to-normal organ SUV ratios measured with 68 Ga-DOTATATE PET compared with 177 Lu-DOTATATE SPECT in patients with neuroendocrine tumors

Affiliations

Differences in tumor-to-normal organ SUV ratios measured with 68 Ga-DOTATATE PET compared with 177 Lu-DOTATATE SPECT in patients with neuroendocrine tumors

Ka Kit Wong et al. Nucl Med Commun. .

Abstract

Background: Our goal is to quantitatively compare radiotracer biodistributions within tumors and major normal organs on pretherapy 68 Ga-DOTATATE PET to post-therapy 177 Lu-DOTATATE single-photon emission computed tomography (SPECT) in patients receiving peptide receptor radionuclide therapy (PRRT).

Methods: PET/CT at ~ 60 min postinjection of Ga-68 DOTATATE and research 177 Lu-SPECT/CT imaging ~ at 4 h (SPECT1) and ~ 24 h (SPECT2) post-cycle#1 were available. Manual contours of lesions on baseline CT or MRI were applied to co-registered SPECT/CT and PET/CT followed by deep learning-based CT auto-segmentation of organs. Tumor-to-normal organ ratios (TNR) were calculated from standardized uptake values (SUV) mean and SUV peak for tumor, and SUV mean for non-tumoral liver (nliver), spleen and kidney.

Results: There were 90 lesons in 24 patients with progressive metastatic neuroendocrine tumor. The correlation between PET and SPECT SUV TNRs were poor/moderate: PET versus SPECT1 R 2 = 0.19, 0.21, 0.29; PET versus SPECT2 R 2 = 0.06, 0.16, 0.33 for TNR nliver ,TNR spleen ,TNR kidney , respectively. Across all patients, the average value of the TNR measured on PET was significantly lower than on SPECT at both time points ( P < 0.001). Using SUV mean for tumor, average TNR values and 95% confidence intervals (CI) were PET: TNR nliver = 3.5 [CI: 3.0-3.9], TNR spleen = 1.3 [CI, 1.2-1.5], TNR kidney = 1.7 [CI: 1.6-1.9]; SPECT1: TNR nliver = 10 [CI: 8.2-11.7], TNR spleen = 2.9 [CI: 2.5-3.4], TNR kidney = 2.8 [CI: 2.3-3.3]; SPECT2: TNR nliver = 16.9 [CI: 14-19.9], TNR spleen = 3.6 [CI: 3-4.2], TNR kidney = 3.6 [CI: 3.0-4.2]. Comparison of PET and SPECT results in a sphere phantom study demonstrated that these differences are not attributed to imaging modality.

Conclusions: Differences in TNR exist for the theranostic pair, with significantly higher SUV TNR on 177 Lu SPECT compared with 68 Ga PET. We postulate this phenomenon is due to temporal differences in DOTATATE uptake and internalization in tumor as compared to normal organs.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Baseline diagnostic images used to define lesions and co-registered pre-therapy 68Ga-DOTATATE PET/CT and post-therapy 177Lu-DOTATATE SPECT/CT images demonstrating higher uptake in tumor relative to normal organs in the SPECT images compared with the PET image. The maximum intensity projections (MIP) with lesions (red), normal liver (green), kidney (blue) and spleen (magenta) VOIs used to extract SUV metrics are also shown. A) Patient L20 with a 29 mL hepatic lesion. TNRnliver: PET = 2.0, SPECT1 = 21.2, SPECT2 = 32.4; TNRspleen: PET = 1.0, SPECT1 = 7.9, SPECT 2 = 8.8; TNRkidney: PET = 1.5, SPECT 1 = 6.6, SPECT 2 = 6.5. B) Patient L14 with a 1045 mL hepatic lesion. TNRnliver: PET = 1.3, SPECT 1 = 11.3, SPECT2 = 17.2; TNRspleen: PET = 0.8, SPECT1 = 6.2, SPECT 2 = 6.1; TNRkidney: PET = 0.8, SPECT1 = 2.9, SPECT2 = 3.0. This patient also has a large mesenteric lymph node evident on the MIP. PET and SPECT images are displayed on the same SUV scale.
FIGURE 2.
FIGURE 2.
SUV values measured at the first (~ 4 h p.i.) 177Lu SPECT/CT imaging time point versus SUV values measured on 1 h p.i. 68Ga PET/CT. The points in red indicate lesions outside the liver. The line of equivalence is indicated in black. SUV values measured at the second (~ 24 h p.i.) 177Lu SPECT/CT imaging time point versus SUV values measured on 1 h p.i. 68Ga PET/CT are shown in Supplemental Figure 1.
FIGURE 3.
FIGURE 3.
Tumor-to-normal organ SUV ratios (calculated using tumor SUVmean) measured on SPECT vs. PET. The points in red indicate lesions outside the liver. Tumor-to-normal organ SUV ratios (calculated using tumor SUVpeak) measured on SPECT vs. PET are shown in Supplemental Figure 2.
FIGURE 4.
FIGURE 4.
Phantom results comparing 68Ga PET and 177Lu SPECT images and sphere-to-background SUV ratios. The SPECT versus PET Pearson correlation R2 value for SUVmean is 0.99 and for SUVpeak is 0.75. The true sphere-to-background SUV ratio is 6.2 for the 177Lu phantom and 6.4 for the 68Ga phantom. Data points from left to right correspond to 2, 4, 8, 16, 30, and 114 mL spheres.

References

    1. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. The New England journal of medicine 2017; 376 (2):125–135. - PMC - PubMed
    1. Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2019; 60 (7):937–943. - PubMed
    1. Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. European journal of nuclear medicine and molecular imaging 2013; 40 (5):800–816. - PMC - PubMed
    1. Mahajan S, O’Donoghue J, Weber W, Bodei L. Integrating Early Rapid Post-Peptide Receptor Radionuclide Therapy Quality Assurance Scan into the Outpatient Setting. Journal of nuclear medicine & radiation therapy 2019; 10 (1). - PMC - PubMed
    1. Ezziddin S, Lohmar J, Yong-Hing CJ, Sabet A, Ahmadzadehfar H, Kukuk G, et al. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Clinical nuclear medicine 2012; 37 (6):e141–147. - PubMed

MeSH terms